SOURCE: StockCall

StockCall

August 26, 2011 08:15 ET

Research on Quest Diagnostics Inc. and Covance Inc. - Medical Laboratories and Research Facing Potential Challenges

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Aug 26, 2011) - www.stockcall.com/ offers investors comprehensive research on the Medical Laboratories & Research industry and has completed analytical research on Quest Diagnostics Inc. (NYSE: DGX) and Covance Inc. (NYSE: CVD). Register with us today at www.stockcall.com/ to have free access to these researches.

The Medical Laboratories and Research sector faces some potential headwinds pertaining to the way in which Big Pharma is now looking to pad its pipelines. While revenue in the contract research business grew 15% in 2010, this came after a few years of research cuts by Big Pharma. The pharmaceutical sector as a whole faces a substantial slate of looming patent cliffs that will require it to shore up pipelines. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Medical Laboratories & Research industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the Medical Laboratories & Research industry can have easy and free access to our analyst research and opinions on Quest Diagnostics Inc. and Covance Inc.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

Still, it appears that Big Pharma is often more interested in making strategic partnerships with companies in the Medical Laboratories and Research sector which will result in some major cost increases and possible consolidation. Covance Inc., for example, which saw its earnings grow 19% in the second quarter thanks to robust growth in its backlogs, has partnered with Sanofi. Investors looking for free research on Covance Inc. are welcome to sign up at www.stockcall.com/CVD260811.pdf.

Companies in the Medical Laboratories and Research sector with clinical diagnostic exposure have been suffering from lower patient visits. It is possible that the down economy is pushing consumers to trim their budgets in the health care space, motivating them to put off seeing a doctor and running tests until they feel more financially secure. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

Quest Diagnostics Inc., for instance, saw a 0.9% drop in clinical testing volume compared with the previous year during its most recently reported quarter. Improvement in the macroeconomic landscape would likely have positive effects on this trend and benefit the sector as a whole. Investors looking for free research on Quest Diagnostics Inc. are welcome to sign up at www.stockcall.com/DGX260811.pdf.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information